Fundraising Fox
/Companies
Sign in

Larimar Therapeutics

NASDAQ: LRMR

Bala Cynwyd, US · Delaware corporation · 1 known investors

Find your way into Larimar Therapeutics

Larimar Therapeutics is a clinical-stage biotechnology company developing nomlabofusp, a subcutaneously administered protein designed to deliver an essential protein to mitochondria in patients with Friedreich's ataxia, a rare genetic disease characterized by severe protein deficiency. The company leverages proprietary cell-penetrating peptide technology to enable delivery of therapeutic molecules across cell membranes for treating rare intracellular disorders.

Biotech

Founders & leadership

MC
Michael CelanoChief Financial Officer
CB
Carole Ben Maimon, MDPresident and CEO
CS
Carole S. Ben-MaimonPresident and Chief Executive Officer
TO
Thomas O. DanielNamed on SEC filing
TH
Thomas HamiltonNamed on SEC filing
FE
Frank E. ThomasNamed on SEC filing
PB
Peter BarrettNamed on SEC filing
JT
Joseph TruittNamed on SEC filing

Board

JL
Jonathan LeffBoard director

Investors · 1

Funding

SEC filings, press & company announcements

$162.1M disclosed across 2 of 3 rounds · 2020–2026

  • Undisclosed amountfollow-on equity offeringFeb 2026
    Source ↗
▶$82.1MraisedJun 2020 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jonathan LeffDirector
  • Thomas O. DanielDirector
  • Thomas HamiltonDirector
  • Michael CelanoExecutive Officer
  • Frank E. ThomasDirector
  • Carole Ben Maimon, MDExecutive Officer, Director
  • Peter BarrettDirector
  • Joseph TruittDirector
Offering amount
$82.1M
Amount sold
$82.1M
First sale
May 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$80MraisedJun 2020 · 24 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jonathan LeffDirector
  • Thomas O. DanielDirector
  • Peter BarrettDirector
  • Joseph TruittDirector
  • Frank E. ThomasDirector
  • Thomas HamiltonDirector
  • Michael CelanoExecutive Officer
  • Carole Ben Maimon, MDExecutive Officer, Director
Offering amount
$80M
Amount sold
$80M
Sales commissions
$4.8M
Placement agents
MTS Partners
First sale
May 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$914.7Mvaluation at IPOJan 2015 · $35.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Frequently asked questions

What does Larimar Therapeutics do?
Larimar Therapeutics is a clinical-stage biotechnology company developing nomlabofusp, a subcutaneously administered protein designed to deliver an essential protein to mitochondria in patients with Friedreich's ataxia, a rare genetic disease characterized by severe protein deficiency. The company leverages proprietary cell-penetrating peptide technology to enable delivery of therapeutic molecules across cell membranes for treating rare intracellular disorders.
Who are Larimar Therapeutics's investors?
Larimar Therapeutics's investors include Third Rock Ventures.
How much funding has Larimar Therapeutics raised?
Larimar Therapeutics has disclosed $162.1M raised across 2 of its 3 known rounds.
Where is Larimar Therapeutics headquartered?
Larimar Therapeutics is headquartered in Bala Cynwyd, US.